1. Introduction {#s0005}
===============

Effective medications are urgently needed to combat the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). At present, no treatment is available, apart from symptomatic interventions, but many vaccine- and drug-based approaches are being investigated worldwide. Drugs such as arbidol, remdesivir, favipiravir and the antibiotic teicoplanin are currently undergoing clinical trials in different countries ([@bb0050]; [@bb0210]). The drugs tested also include chloroquine (CQ) and its analog hydroxychloroquine (HCQ) found to be efficient on SARS-CoV-2. A study with a small cohort of patients has shown that a treatment with HCQ can markedly reduce, if not eliminate, the viral load in patients with coronavirus disease 2019 (COVID-19) ([@bb0280]). This first clinical observation corroborated preclinical data suggesting that HCQ was effective against the SARS-CoV-2 virus-infected cells in vitro ([@bb0530]). CQ is also active, although less efficacious than HCQ ([@bb0270]; [@bb1095]). HCQ, known for decades for treatment of malaria, is a good antiviral agent active against most coronaviruses, including SARS-CoV-1 ([@bb0195]) but definitive proofs of its clinical efficacy to treat SARS-CoV-2 patients are awaited. At present, its safety/efficacy ratio is controversial ([@bb0725]; [@bb0855]).

Other drugs active against SARS-CoV-2 are actively studied, such as protease inhibitors. But drugs with distinct and varied mechanisms of action are needed to propose efficient drug combinations. Here we propose an innovative approach based on the use of the saponin drug glycyrrhizin, which we believe can be useful to combat the virus infection and to treat the associated respiratory symptoms. We searched for a drug that could not only inhibit viral replication but also interfere with the entry of the virus into cells. On the one hand, we reasoned that an amphiphilic compound like a saponin could interfere with the virus entry into cells, owing to the well-known membrane effects of this class of compounds. On the other hand, we considered that a target associated to "danger-signals" in cells, like HMGB1, could be a useful to trigger an immune response. A deep analysis of the literature was performed to identify this drug which, we think, should be considered for the treatment of COVID-19, for the reasons detailed below.

2. Glycyrrhizin (GLR), a natural product {#s0010}
========================================

Glycyrrhizin, also called glycyrrhizic acid (GLR), is a triterpenoid saponin mainly isolated from the roots (Glycyrrhizae Radix) of the plants *Glycyrrhiza glabra* (typically cultivated in Europe, henceforth called European licorice) and *G. uralensis* Fisch and *G. inflata* Bat (used in the Chinese Pharmacopoeia) ([@bb0680]; [@bb0315]; Wang, [@bb0125]). *G. glabra* contains more than 10 GLR-related saponins ([@bb0770]). The product has been found also in other *Glycyrrhiza* species such as *G. triphylla* ([@bb0795]) and in an edible marine alga *Hizikia fusiformis* (Harvey) Okamura, a brown seaweed ([@bb0790]; [@bb0950]). The name derives from the Greek word 'glykosrhiza' or sweet root. GLR is commonly isolated from Glycyrrhizae Radix in the form of a monoammonium salt (C~42~H~61~O~16~\_NH~4~), but occasionally studies are performed with the magnesium salt of 18β-glycyrrhizic acid (magnesium isoglycyrrhizinate) ([@bb0080]; [@bb0895]; [@bb1190]). Specific methods have been developed to monitor the extraction process and for GLR dosages in biological media ([@bb0995]; [@bb1120]; [@bb1130]).

GLR is a glycoside of glycyrrhetinic acid (GA, the sapogenin moiety) with two residues of glucuronic acid ([Fig. 1](#f0005){ref-type="fig"} ). GA is the major metabolite of GLR, together with 3-O-mono-β-D-glucuronyl-glycyrrhetinic acid (3MGA) and a minor sulfated metabolite ([@bb0355]; [@bb0640]). Orally administered GLR is metabolized into GA by intestinal bacteria and absorbed via the intestine. Nevertheless, GLR is detected in human plasma after oral administration of a clinical dose of GLR ([@bb0875]). Both oral and intravenous formulations of GLR are used in Human.Fig. 1(a) Structures of glycyrrhizic acid (GLR) and glycyrrhetinic acid (GA). GLR is composed of a central saponin core flanked by a carbohydrate side chain at C-3. Below, the molecular models of GLR and GA show the accessible surface and hydrophilic (purple) and lipophilic (green) sites. For GLR, the central triterpenoid aglycone, largely hydrophobic, is bound to a hydrophilic sugar chain. The model of GA (aglycone) is shown for comparison. Models were built with Discovery Studio 2020 Client, Dassault Systemes Biovia Corp..Fig. 1

The natural product exists as two epimers 18α-glycyrrhizic acid (18α-GLR) and 18β-glycyrrhizic acid (18β-GLR), both active although the 18β-isomer seems to be more potent than the 18α-isomer. Indeed, 18β-glycyrrhetinic acid (IC~50~ = 8.9 μM) was found to be about 2-fold more active than GLR (IC~50~ value of 20.1 μM) and 11-fold more potent than 18α-glycyrrhetinic acid (IC~50~ = 104.3 μM) in an enzyme BACE1 inhibition assay (butyrylcholinesterase and β-site amyloid precursor protein cleaving enzyme 1) ([@bb0950]). Bioproduction methods using metabolically engineered *Saccharomyces cerevisiae* (yeast cell factories) are being developed as an alternative "greener" approach to produce GLR ([@bb0990]). β-glucuronidase enzymes can be used to bio-transform GLR into GA ([@bb0485]). The product is often used as a natural emulsifier and gel-forming agent in foodstuffs, beverages and cosmetics. GLR is approved for use as an additive in foods since 1985 in the US and has the Generally Recognized as Safe (GRAS) status. In biology and medicine, GLR has been extensively studied for its very diverse pharmacological properties, including anti-inflammatory, antioxidative, anti-allergenic, antimicrobial, antiviral, antiparasite, anticancer properties. The properties and applications of GLR and GLR-containing extracts have been reviewed previously ([@bb0120]; [@bb0230]; [@bb0420]; [@bb0620]). Nevertheless, in view of the increasing scientific interest in this product and the current COVID-19 pandemia, we decided to write a review essentially focus on the antiviral properties of the drug, to analyze its potential use for the treatment of coronavirus infections.

3. GLR as a drug used in human {#s0015}
==============================

In Japan, GLR has been used for more than 40 years as treatment for liver diseases, in particular to treat chronic hepatitis ([@bb0475]). Intravenous GLR therapy is generally well tolerated and considered effective in different forms of hepatitis ([@bb0905]). It is an efficient hepatoprotective medication in patients with chronic hepatitis C ([@bb0900]) and more broadly to protect from a variety of hepatic diseases such as chronic viral hepatitis, drug- or chemical-induced liver injury, nonalcoholic fatty liver disease, autoimmune hepatitis and hepatocellular carcinoma ([@bb0500]). Most of these effects can be attributed to the drug inhibitory activity on inflammatory cytokines in the liver and activation of CD8^+^ T cells and Tregs proliferation ([@bb0275]). One of the main GLR-containing preparation is intravenous Stronger Neo-Minophagen C (SNMC, from Minophagen Pharmaceutical Co. Ltd., Tokyo) used for suppression of hepatitis activity and prevention of disease progression in patients with hepatitis B virus- and HCV-induced chronic hepatitis. SNMC is currently investigated for the treatment of acute hepatitis post transarterial chemoembolization (TACE) therapy in patients with hepatocellular carcinoma ([NCT04015245](NCT04015245){#ir0020}).

GLR is also used to treat different forms of cutaneous inflammation ([@bb0410]). For example, combined with methotrexate, GLR has been used successfully to treat erythrodermic psoriasis ([@bb0815]; [@bb1110]; [@bb1120]). But one of the most frequent inflammatory skin diseases treated with GLR (at least in Japan and Korea) is atopic dermatitis (AD). Recently, it was reported that GLR inhibited the release of cytokines IL-4 and IL-13 in a murine model of AD ([@bb0440]) and another study showed that, through inhibition of the protein HMGB1 (High-Mobility Group protein B1), GLR can ameliorate the symptoms of AD in a mouse model with the drug injected daily intraperitoneally ([@bb1010]). By sequestering HMGB1 (see mechanism below), GLR modulates the production of inflammatory cytokines such as IL-18, to prevent contact dermatitis induced by contact allergens ([@bb0260]). The activity of GLR against cutaneous inflammation should be kept in mind considering the cutaneous manifestations in COVID-19-positive patients ([@bb0920]).

The drug is considered as having a good safety and economical profile. Its clinical use is increasing. In recent years, we noted the development of different clinical trials to investigate the benefit of GLR in multiple pathologies such as depression ([@bb0085]), Parkinson\'s disease ([@bb0690]) and different cancers, such as hepatocellular carcinoma and pancreatic cancer ([@bb0420]).

4. GLR antiviral activities {#s0020}
===========================

Over the past thirty years, the effects of GLR against a variety of human viruses have been reported ([Fig. 2](#f0010){ref-type="fig"} ). The anti-HIV1 activity of GLR is well documented ([@bb0020]; [@bb0030]; [@bb0045]; [@bb0055]; [@bb0065]; [@bb0180]; [@bb0175]; [@bb0520]; [@bb0525]; [@bb0590]; [@bb0615]; [@bb0610]; [@bb0740]; [@bb0870]; [@bb1035]). GLR dose-dependently inhibits virus-cell binding and the replication of HIV-1 in human cells ([@bb0360]). The drug has been tested in AIDS patients, at a dose of 400--1600 mg/day given i.v., and the viral antigen was no longer detected at the end of the treatment course, suggesting a marked inhibition of HIV-1 replication ([@bb0310]). GLR effectively inhibited HIV replication in cultures of peripheral blood mononuclear cells from HIV-seropositive patients ([@bb0760]).Fig. 2Antiviral activities of GLR. The drug is active against aa number of viruses in vitro. In vivo activities have been reported with a few viruses, notably HIV-1. But the main antiviral activity is against the hepatitis viruses A, B and C. The drug is used in Human to treat liver diseases, notably chronic viral hepatitis.Fig. 2

The drug is also active against some animal viruses. It functions as an immune-stimulant against duck hepatitis virus (DHV) ([@bb0675]; [@bb0840]) and showed a marked direct antiviral activity, leading to complete inhibition of cell infection, against the avian infectious bronchitis virus (IBV) ([@bb0470]). This antiviral activity coupled with a hepatoprotective effect ([@bb0490]; [@bb0495]) support the use of a licorice extract supplementation in poultry diets ([@bb0015]). A study with chicken HD11 macrophages indicated that GLR activates the immune regulatory functions, notably promoting the expression of cytokines IFN-γ, IL-6, and IL-10, and the production of nitric oxide ([@bb0975]; [@bb0970]). GLR is also effective against the porcine reproductive and respiratory syndrome virus (PRRSV, an enveloped single positive-strand RNA virus, Arterivirus), acting mainly at the virus penetration stage, not later steps of adsorption or release of PRRSV in its life cycle ([@bb0220]). The GLR derivative dipotassium glycyrrhetate inhibits PRRSV replication in vitro ([@bb1020]). Interestingly, a recent study revealed that the use of a polymeric form of GLR, to form monodisperse carbon dots (spherical carbon particles), leads to remarkable antiviral effects, with inhibition of PRRSV invasion and replication, inhibition of the accumulation of intracellular reactive oxygen species caused by PRRSV infection, and stimulation of antiviral innate immune responses. Moreover, this GLR-based product was also effective against the related nidovirus PEDV (porcine epidemic diarrhea virus) ([@bb0915]). In fact, GLR inhibits the entry and replication of PEDV (but not virus assembly and release), as well as the production of the proinflammatory cytokines IL-1β, IL-6, IL-8 and TNFα. More precisely, GLR inhibits the increase of these proinflammatory cytokines induced by PEDV infection ([@bb0340]).

5. GLR and SARS-associated coronaviruses {#s0025}
========================================

In 2003, it was reported that GLR effectively inhibited the replication of two clinical isolates of SARS-associated coronavirus (FFM-1 and FFM-2) in Vero cells. The drug was found to inhibit the cytopathic effect of the virus with an EC~50~ of 300 mg/ml, while being non cytotoxic to the host cells. GLR inhibited virus replication but also the adsorption and penetration of the virus into cells ([@bb0155]). The mechanism of action at the origin of this activity was not known at that time but a drug-induced production of nitrous oxide synthase was mentioned, suggesting that nitrous oxide could be responsible for the inhibition of virus replication ([@bb0155]). GLR also revealed active when it was tested against 10 clinical isolates of SARS coronavirus in infected Vero-E6 cells but the activity was limited in time. Apparently, the rapid metabolization of the drug limits the drug exposure, not permitting to reach the effective concentration. After an intravenous administration of GLR at a dose of 200 mg, the peak serum level was only 80 μg/ml, insufficient to induce the desired biological effects (EC~50~ \> 400 μg/ml) ([@bb0100]). The modification of the GLR structures, notably to make amide derivatives and amino-acid conjugates can increase considerably the activity against SARS-CoV but it can be at the expense of an increased cytotoxicity ([@bb0325]).

6. GLR and respiratory distress syndrome {#s0030}
========================================

Different elements suggest that GLR can be useful to treat respiratory infections and acute respiratory distress syndrome (ARDS). First, several medicinal plant preparations containing GLR are used for a long time to treat upper respiratory infections. This is the cases of the GLR-containing Siji-kangbingdu herbal mixture, Maxing Shigan decoction and Lianhua-Qingwen capsules, used in China to treat upper respiratory infections ([@bb0375]; [@bb0455]; [@bb1100]). It is also the case for the GLR-containing traditional medicine Macmoondongtang used to treat pulmonary disease in Korea ([@bb0445]). Second, a clinical study performed in Japan in 2002 among military patients treated for upper respiratory tract infections (URTI) has shown that GLR therapy was associated with a shorter hospitalization, lower-grade fever and lower cost of therapy compared with controls. It was concluded that GLR could be useful to patients with URTI without acute bacterial infections ([@bb1070]). Experimental studies have proposed also the use of GLR to treat respiratory distress syndrome on the basis of the capacity of the product to reduce the pulmonary accumulation of platelets ([@bb1125]) and to inhibit proinflammatory cytokines released from activated inflammatory cells in the initial phase of the syndrome ([@bb0435]). The proinflammatory cytokine IL-33 is likely a major factor in ARDS and its expression is enhanced in the serum, bronchoalveolar fluid and lung tissue of mice with LPS-induced lung injury. A treatment with GLR was found to reduce the levels HMGB1 and IL-33 in the serum and bronchoalveolar fluid compared to the controls ([@bb0245]). This laboratory study supports the potentially beneficial effect of GLR to reduce ARDS. Other experimental studies using models of LPS-induced acute lung injury have reported beneficial effects of GLR, with evidences of drug-induced inactivation of the toll-like receptor (TLR) pathway ([@bb0405]).

7. Improved GLR formulation for in vivo administrations {#s0035}
=======================================================

The amphiphilic and anisotropic structure of GLR led to the formation of rod-like micelles and fibrils that self-assembled into a fibrillary network ([@bb0730]). The hydrophobic aglycone moieties can interact on a lateral basis yielding a head-to-head configuration which exposes the hydrophilic di-glucuronic acid heads to the aqueous phase, as illustrated in [Fig. 3](#f0015){ref-type="fig"} . The process is highly pH-dependent; the drug is practically insoluble at pH \<4.5, rod-like micelles form at pH 5--6 and dissociate into monomers at pH 7 ([@bb0595]). The self-assembling of GLR into a fibrillar network leads to the formation of micro-structures ([Fig. 4](#f0020){ref-type="fig"} ) with specific mechanical properties ([@bb0480]; [@bb0960]; [@bb0955]; [@bb0965]). The self-assembly of supramolecular GLR nanofibrils can be exploited to form ultrastable, thermostimulable, and processable foams ([@bb0555]).Fig. 3Illustration of the self-assembling of GLR to form a fibrillar network. Molecules of GLR associate in an anti-parallel orientation, with stacking of the hydrophobic sapogenin moieties to form fibrils. Depending on the conditions, GLR can also for micelles and other structures which can be used to entrap other small molecules, as a drug delivery system. The entrapment of molecules into a fibrillar network is illustrated.Fig. 3Fig. 4The fibrillar self-assembly of GLR. (a) Confocal laser scanning microscopy image of an emulsion gel stabilized by 4 wt% GLR nanofibrils (*Thioflavin T* fluorescence highlights GLR the fibrillar network). (b) 0.2 wt% GLR nanofibrils observed by atomic force microscopy. (c) 0.1 wt% GLR nanofibrils observed by transmission electron microscopy. (d) Scanning electron microscopy image of the aqueous phase network of an emulsion gel stabilized by 4 wt% GLR nanofibrils. (images kindly provided by Prof. Xiao-Quan Yang, Dpt of Food Science and Technology, South China University of Technology, Guangzhou, China).Fig. 4

Different drug delivery systems specifically adapted to GLR and/or GA have been elaborated ([@bb0075]). Notably, an encapsulation of GLR together with the flavonoid silibinin into nano-liposomes has been proposed for the treatment of hepatocellular carcinoma. Such a formulation reduces the half maximal inhibitory concentration (IC~50~ to reduce the growth of HepG2 cells in vitro) by about 10-fold for the encapsulated product versus the free drug ([@bb0670]). The preparation of GLR-based nano-liposomes has been optimized ([@bb0535]). The drug can be encapsulated as well as the liquorice extract, into liposomes and other types of vesicles, such as phospholipid-Na hyaluronate vesicles called hyalurosomes ([@bb0090]). An alternative to conventional liposomes is the development of niosomes, as nonionic surfactant vesicles (NSV), which are prepared with Tween 20 and cholesterol, plus cholesteryl hemisuccinate to obtain stable but pH-sensitive vesicles which can release a payload at acidic pH. Such NSV loaded with GLR were found to display significant anti-inflammatory and antinociceptive effects in mice. Entrapment of GLR (1% *w*/*v*) into niosomes could be a convenient system to permit a prolonged release of the active principle ([@bb0580]). Improvements have been proposed to further ameliorate the stability, skin permeability and capacity of these niosomes to deliver the drug, with the use of gel-forming polysaccharides ([@bb0170]).

GLR-containing vesicles can serve to transport and deliver GLR, but also to facilitate the transportation and delivery of co-loaded drugs. Indeed, GLR is viewed as a multifunctional carrier for a variety of hydrophobic molecules, by virtue of its amphiphilic properties ([Fig. 1](#f0005){ref-type="fig"}, [Table 1](#t0005){ref-type="table"} ). The Solvent Accessible Surface Area (SASA) for GLR is large, offering a significant potential to interact with both hydrophilic and hydrophobic molecules, and with multiple H-bond donor/acceptor sites ([Table 1](#t0005){ref-type="table"}). GL complexes or micelles with many drugs have been reported, for examples with anticancer drugs such as paclitaxel, podophyllotoxin and camptothecin ([@bb0070]; [@bb1015]; [@bb1075]). Not only GLR can enhance the solubility of poorly soluble drugs but it can increase also their passive diffusion through cell membranes. The capacity of GLR to interact with phospholipids-based membrane models and to cause transient pore formation has been elegantly modeled. GLR was shown to embark a few water molecules within the membrane and to make the membrane thinner locally ([@bb0775]) but apparently it does not simply induce transient local pores in the membrane; the mechanism is more complex and seems to involve a drug-induced decrease in cholesterol within the lipid bilayer ([@bb0800]). Therefore, the drug can be used as nonselective delivery vector for a variety of drugs ([@bb0780]; [@bb0850]). A nice example has been reported recently with the GLR-mediated enhanced delivery of the anti-helminthic drug praziquantel, showing that the self-association of GLR molecules plays an important role in increasing the solubility and transport to the cell surface of praziquantel ([@bb0395]). A water-soluble preparation of disodium glycyrrhizinate micelles with inclusion of praziquantel proved to be a good anthelmintic agent in vitro and in vivo, owing to a significant improvement of the bioavailability of praziquantel ([@bb0025]; [@bb0605]).Table 1Computed physico-chemical properties of GLR and GA.Table 1ProductGLRGAMolecular weight822.9470.7Dipole moment (D)11.94.3Total solvent accessible surface area (SASA) (Å^2^)[a](#tf0005){ref-type="table-fn"}1121.8703.2Hydrophobic SASA631.5551.8Hydrophilic SASA477.5138.0Molecular volume (Å^3^)2258.21415.0Donor hydrogen bonds82Acceptor hydrogen bonds164log P (octanol/water)2.25.2log S (aqueous solubility)−6.6−6.6[^1]

8. Membrane effects of GLR: cholesterol-dependent disorganization of lipid rafts {#s0040}
================================================================================

The antiviral activity of GLR relies on both cytoplasmic and membrane effects. The drug inhibits hepatitis A virus penetration of the plasma membrane ([@bb0180]) and suppresses the secretion of viral antigens, such as the hepatitis B surface antigen. GLR inhibits the sialylation of the antigen and intracellular transport to induce its accumulation in cytoplasmic vacuoles in the Golgi apparatus ([@bb0765]; [@bb0885]). The saponin reduces the movement of molecules within the membrane and thus impedes the formation of fusion pores necessary for the entry of viruses. In fact, the drug lowers the membrane fluidity and thus suppresses infection by different viruses, such as HIV-1, HTLV-1, influenza A virus and vesicular stomatitis virus, but not by poliovirus ([@bb0300]). It is very important to underline that GLR is a non-lytic saponin. In contrast to other saponins like digitonin, GLR shows weak permeabilizing effects and thus has a very low hemolytic profile ([@bb0285]). It does not destroy the whole membrane integrity and induces very little leakage from liposomes compared to other saponins ([@bb0565]). In the context of the Herpes simplex virus (HSV), it has been shown that GLR reduced adhesion force and stress between cerebral capillary vessel endothelial cells and polymorphonuclear leukocytes, thereby attenuating the inflammatory responses to HSV ([@bb0345]). In the context of HIV-1, the drug has been shown to bind to the conserved core sequence of V3 loop in the surface glycoprotein gp120 with a sub-micromolar affinity ([@bb0515]).

At least a part of the membrane effects of GLR can be linked to an interaction with cholesterol ([Fig. 5](#f0025){ref-type="fig"} ) and the reduction in cholesterol domain in membrane. The interaction of saponins with cholesterol is a main element of their mechanism of action, and their capacity to induce membrane disorganization and in some cases disruption. For example, cholesterol recognition by the anticancer saponin OSW-1 is essential for the subsequent membrane permeabilization ([@bb0565]). Cholesterol is known as a very important modifier of the dynamics and structural properties of lipid membranes. Compared to other saponins like digitonin, OSW-1 and Quillaja saponin, GLR shows very weak membrane permeabilizing effects on membranes from lysosomes or red blood cells ([@bb0285]). Nevertheless, GLR interacts with cholesterol and this interaction modifies the membrane permeability to ions and small molecules ([@bb0775]). A study using artificial membranes prepared at 1.5:1 cholesterol-to-phospholipid mole ratio has shown that GLR reduced cholesterol domain formation by 54.9% ([@bb0585]). Not only GLR decreases the level of cholesterol of lipid rafts but also inhibits the translocation of TLR-4 to lipid the rafts ([@bb0250]; [@bb0255]). This mode of action is distinct from that of conventional cholesterol-lowering statins. Consequently, combinations of GLR and the statins atorvastatin and simvastatin (leading to combo named atorvaglyzin and simvaglyzin) have been proposed to reinforce the cholesterol-lowering effect ([@bb0705]; [@bb0845]; [@bb0935]).Fig. 5Molecular models of the interaction between GLR (purple) and cholesterol (green). The two different orientations show the stacking of the two hydrophobic parts of each molecule and the contacts made with the glycoside moiety of GLR which contribute to clamp the cholesterol unit.Fig. 5

We have used molecular modeling to compare the interaction with cholesterol of GLR and platycodin D, a bidesmosic saponin known to exhibit cholesterol-lowering effects ([@bb1160]). As shown in [Fig. 5](#f0025){ref-type="fig"}, the modeling analysis shows that GLR can form stable complexes with cholesterol, mainly via hydrophobic interaction with the sapogenin moiety of GLR. The potential energy of interaction is lower for the complex of GLR with cholesterol (ΔE = −19.5 kcal/mol) compared to that measured for the platycodin D-cholesterol complex (ΔE = −24.3 kcal/mol) and this is in agreement with the very weak hemolytic capacity of GLR. However, the interaction is significant, stronger than with GA and sufficient to induce plasma membrane perturbations. It has been shown that the drug can move within the membrane, with exchange of GLR molecules from solution to the hydrophobic interior of the lipid bilayer ([@bb0775]). Normally, cholesterol makes the bilayer more rigid but the interaction with GLR reduces the rigidification of the membrane, and thus possibly increases membrane permeability. This interaction contributes to the regulation of the size of lipid raft domains observed in the presence of GLR ([@bb0750]). GA was found to interact even more strongly with a raft monolayer model than GLR ([@bb0750]; [@bb0755]). The disorganization of cholesterol-containing lipid rafts by GLR is an important element to consider in the light of a recent work showing that a ganglioside-binding domain of the spike (S) protein of SARS-CoV-2 likely plays a role in the surface attachment of the virus to lipid rafts. This highly conserved domain would facilitate the entry of the virus into respiratory cells. Chloroquine and hydroxychloroquine bind strongly to sialic acids and gangliosides, thereby limiting attachment of the virus via the spike to the gangliosides on the raft platforms ([@bb0235]). A combination with GLR may further inhibit the entry of the virus, via a membrane destabilizing effect. Recently, inhibition of viral lipid-dependent attachment of the virus envelope of the SARS-COV-2 to host cell plasma membrane in vitro, with natural products such as cyclodextrin and sterols, has been proposed as a strategy for reducing SARS-COV-2 infectivity ([@bb0035]). Our proposal is totally in-line with this view.

Lipid rafts play an important role in the life cycle of SARS-coronavirus. The depletion of cholesterol (with methyl-β-cyclodextrin) inhibits the production of coronavirus particles released from infected cells ([@bb0460]). Different studies suggest that lipid rafts serve as an entry port for SARS-CoV ([@bb0150]; [@bb0545]; [@bb1000]). Similarly, the depletion of plasma membrane cholesterol with methyl-β-cyclodextrin or a statin drug considerably reduces the infection by the coronavirus infectious bronchitis virus (IBV) in vitro, presumably impairing the attachment of the virus to the cell surface ([@bb0290]). PEDV and human metapneumovirus (hMPV) can also enter cells through lipid raft-mediated endocytosis ([@bb0135]; [@bb1025]). In fact, lipid rafts play a key role in the endocytosis process of many viruses and, as a corollary, interfering with lipid raft organization is a mechanism to control virus infection. Moreover, this is probably the reason why the impairment of cellular cholesterol metabolism and lipid raft functionality have been evoked as a co-morbidity factor in some viral diseases, such as HIV infection ([@bb0880]).

The cholesterol lowering effect of GLR can explain its antiviral effect against the porcine virus PRRSV, at least partially. Indeed, it has been demonstrated that cell membrane cholesterol is required for porcine nidovirus entry into cells and a drug able to induce cholesterol depletion dose-dependently suppressed the replication of the nidoviruses PRRSV and PEDV ([@bb0365]; [@bb0865]). Similarly, GLR reduces membrane cholesterol and, as discussed above, it is active against those two porcine nidoviruses ([@bb0220]; [@bb0915]). Other viruses also partly depend on membrane cholesterol for entry into cells. This is the case of another coronavirus, the highly neurovirulent porcine hemagglutinating encephalomyelitis virus (PHEV). Here also, a perturbation of membrane cholesterol fluidity (by cholesterol depletion with methyl-β-cyclodextrin in vitro) inhibited the virus endocytic route as well as the viral genome replication and viral protein synthesis ([@bb0510]). Alternatively, PRRSV infection can be inhibited with the use of 25-hydroxycholesterol (25HC) which is normally formed by oxidation of cholesterol by the interferon-α-induced enzyme cholesterol 25-hydroxylase (CH25H). 25HC, as a regulator of cellular cholesterol biosynthesis, is a natural antiviral agent to combat infections by porcine viruses such as PRRSV and TGEV (porcine transmissible gastroenteritis virus) ([@bb0835]; [@bb0830]; [@bb1150]) and other viruses ([@bb1115]). It would be interesting to evaluate the antiviral activity of a combination of GLR and 25HC.

9. Trapping of HMGB1 by GLR {#s0045}
===========================

The pharmacological action of GLR is not limited to the plasma membrane. The drug displays a marked anti-inflammatory activity and modulates the immune system, via an action on multiple pathways such as MAPK and Toll-like receptors signaling pathways ([@bb1175]). The signaling activities of GLR likely derive from its binding to high-mobility group proteins B1 (HMGB1 and possibly HMGB2), thereby inhibiting the DNA-binding and phosphorylation of the protein ([@bb0745]). Structural studies have revealed that GLR can physically bind to HMGB1 and a modeling study suggested that the drug can also bind to the nuclear HMGB1-DNA complex ([@bb1060]). GLR shows a modest affinity for HMGB1 (K~d~ \~ 150 μM, an abundant protein) via a binding on the shallow concave surface formed by the two arms of the HMGB protein, as represented in [Fig. 6](#f0030){ref-type="fig"} . GLR derivatives bearing amino acid residues on the carbohydrate chain have been shown also to bind to HMGB1 and block its activity, but they were not significantly more potent than GLR itself ([@bb0215]). GLR does not distort the protein structure upon binding but forms stable kissing complexes with the HMG protein. The stability of the drug-protein complex is mainly assured by favorable hydrophobic and electrostatic interactions between the triterpene scaffold of GLR and several key amino acid residues of the proteins (such as Y15, F37, A16 and V19) ([@bb0635]).Fig. 6Global view of the complexes formed between GLR (*top*) or GA (*bottom*) with the HMG box motif of the B domain of HMG1 (PDB code: [1HME](pdb:1HME){#ir0005}). The procedure used to construct the models is described [Table 2](#t0010){ref-type="table"}.Fig. 6

We have used molecular modeling to compare the overall binding of GLR and GA to HMGB1, on the basis of the crystallographic structure of the HMG box motif in the B domain of HMG1 (PDB code: [1HME](pdb:1HME){#ir0025}) ([@bb1030]). It is an L-shaped small protein (77 amino acids) with three alpha-helices defining two arms ([Fig. 6](#f0030){ref-type="fig"}). Our molecular docking analysis indicates that GLR can form much more stable complexes with this HMG box domain than GA. The potential energy of interaction is 2.4 times better (more negative) with GLR than with GA. The Gibbs free energy of hydration (free enthalpy of hydration) is also much more favorable for GLR compared to GA ([Table 2](#t0010){ref-type="table"} ). The difference illustrates the major contribution of the carbohydrate moiety of GLR to the HMG interaction. A more detailed analysis of the binding shows the important contribution of both H-bonds and hydrophobic drug-protein interactions ([Fig. 7](#f0035){ref-type="fig"} ). GLR, with a much higher number of H-bond donor/acceptor atoms ([Table 1](#t0005){ref-type="table"}), is better adapted to fit into the concave side of the HMG box structure. The disaccharide motif of GLR sits on the L-structure, interacting with two alpha-helices. The contact map in [Fig. 8](#f0040){ref-type="fig"} illustrates the higher number of interactions observed with the GLR-HMG structure, compared to the GA-HMG one, with in particular the major molecular contacts provided by the glycosyl moiety. In both cases, the aglycone hydrophobic core interacts about similarly with the protein (implicating residues Leu-16, Leu-63 and Lys-8, Lys-66 for both ligands) but in the case of GLR, the two glucuronic acid residues provide extra attachment sites to the protein (in particular with Lys-24, Lys-59 and Glu-20 residues). There is no doubt that GLR is a very well adapted HMG ligand. Our docking analysis is coherent with the published NMR structure of GLR bound to HMGB1 ([@bb0635]) and highlights the contribution of the glycoside moiety of GLR to the protein interaction.Table 2Calculated potential energy of interaction (ΔE) and free energy of hydration (ΔG) of the drug-HMG box complexes.[a](#tf0010){ref-type="table-fn"}Table 2CompoundΔEΔG(kcal/mol)(kcal/mol)HMG box - glycyrrhizic acid (GLR)−82.10−21.17HMG box - glycyrrhetinic acid (GA)−33.62−14.77[^2]Fig. 7Views of the GLR- and GA-HMG complexes with a focus on the H-bond and hydrophobic surfaces exposed implicated in the protein complex formation. Note the specific contribution of the carbohydrate moiety of GLR to the protein interaction. In both cases, the specific color code is indicated.Fig. 7Fig. 8Binding map contacts for GLR and GA bound to the HMG box.Fig. 8

The binding of GLR to HMGB1 is not extremely tight but sufficiently strong to perturb the various physiological activities of the protein, notably its interaction with other proteins such as the receptor for advanced glycation end products (RAGE), TLR2 and TLR4. The TLR4/HMGB1-dependent anti-inflammatory effects of GLR have been largely documented. In cases of viral hepatitis, GLR alleviates inflammation via a HMGB1-TLR4 signaling pathway ([@bb0810]). Inhibition of this axis also permits to reduce radiation-induced acute lung injury ([@bb1180]) and to protect from ischemia/reperfusion injury ([@bb1065]). By decreasing TLRs activity, GLR can reduce the levels of inflammatory cytokines and the effects of different inflammatory mediators such as the TLR4 ligand nicotinate phosphoribosyltransferase ([@bb0570]). GLR has the capacity to sequester HMGB1, inhibiting its nuclear translocation and/or cellular release. It also inhibits the expression of the protein and downregulates the expression of inflammatory cytokines. Consequently, GLR interferes with several HMGB1-mediated pathological conditions, notably a variety of neurological disorders including traumatic brain injury, epileptic seizures, multiple sclerosis, and Alzheimer\'s and Parkinson diseases ([@bb0685]). In fact, the successfully inhibition of HMGB1 by GLR translates into a variety of effects depending on the cell system and its environment. By modulating HMGB1 protein-binding, GLR (i) alters the epithelial-to-mesenchymal transition ([@bb0095]), (ii) reduces cancer cell growth ([@bb1045]), (iii) reduces pain and inflammation in diabetic neuropathy conditions ([@bb0910]), (iv) attenuates hemorrhagic transformation in ischemic stroke ([@bb0105]), (v) inhibits the tendon\'s inflammatory reactions ([@bb1155]), (vi) reduces the level of circulating, serum HMGB1 in models of lupus nephritis ([@bb0505]; [@bb0515]) and atherosclerosis ([@bb1005]), (vii) attenuates chronic inflammatory pain ([@bb0860]). Given the central roles of HMGB1 both as a transcription regulator in the nucleus and as a circulating damage-associated molecular pattern (DAMP), the targeting of HMGB1 is considered a valid strategy in many diseases: cancer, autoimmune diseases, inflammatory heart diseases, neurological diseases, trauma ([@bb0650]; [@bb0925]; [@bb0940]).

HMGB1 plays important roles in viral infections and the trapping of HMGB1 by GLR has multiple consequences in terms of viral pathogenicity. Different examples can be cited to underline the relationship between HMGB1-GLR binding and viral infection: (i) GLR reduces HMGB1 binding to DNA and thus inhibits influenza virus polymerase activity ([@bb0630]); (ii) GLR inhibits HMGB1 upregulation in cells infected with the respiratory syncytial virus (RSV) and this effect is associated with significant reduction of viral replication ([@bb0575]); (iii) treatment of HBV-infected mice with GLR significantly decreases the intrahepatic recruitment of inflammatory cells ([@bb0820]), (iv) as mentioned above, inhibition of HMGB1 by GLR restricts the entry and replication of PEDV ([@bb0340]), (v) GLR blocks the release of HMGB1 by HSV-2 infected cells and thus abrogates HIV-1 reactivation ([@bb0060]), (vi) the drug can also favor the elimination of HIV-1-infected dendritic cells by this HMGB1 trapping mechanism ([@bb0600]; [@bb0735]). Moreover, HMGB1 inhibition attenuates the proinflammatory response engendered by the PEDV infection. Indeed, PEDV infection induces HMGB1 transcription and its subsequent release. GLR can be used to counteract this effect ([@bb0335], [@bb0340]). Therefore, we could expect a similar advantage using GLR to alleviate the effects of COVID-19. A beneficial effect on the respiratory distress syndrome could be expected also because HMGB1 has a significant role in the development and progression of acute respiratory distress syndrome (ARDS), through the regulation of cytokines such as IL-33. As mentioned above, inhibition of HMGB1 release by GLR is associated with a decrease of the HMGB1-induced up-regulation of IL-33 expression in a mouse model of LPS-induced lung inflammation/injury ([@bb0245]).

A few other HMGB1 inhibitors have revealed interesting antiviral activities such as acteoside (a phenylpropanoid glycoside from Kuding Tea) which blocks HMGB1 release ([@bb0785]) and displays antiviral effects, presumably via its capacity to induce IFN-γ production ([@bb0825]). Similarly, the non-narcotic alkaloid papaverine has been identified recently as a direct inhibitor of the HMGB1/RAGE interaction and a suppressor of the HMGB1-mediated production of pro-inflammatory cytokines ([@bb0890]) and it is also active against influenza viruses and paramyxoviruses ([@bb0010]). But in the present context, our favorite example is chloroquine which has been shown previously to inhibit HMGB1 release in different cell types (macrophages, monocytes, and endothelial cells) in a mouse model of endotoxemia or sepsis ([@bb1090]). Chloroquine downregulates the expression of HMGB1 and reduces the level of serum HMGB1 in a model of chemical-induced acute liver injury ([@bb0190]).

10. Other targets and mechanisms {#s0050}
================================

In addition to HMG proteins, GLR has also been shown to bind to other proteins such as serum albumin ([@bb0980]; [@bb0985]; [@bb0995]) and to recombinant HIV-1 reverse transcriptase to inhibit the protein phosphorylation ([@bb0305]). Binding of GA to the active site of lactate dehydrogenase from *Plasmodium falciparum* (malaria parasite) has been proposed based on molecular modeling, mimicking the binding of chloroquine to the same site and possibly explaining the modest antimalarial activity of GLR ([@bb0385]). Another important enzyme target of GLR is 11β-hydroxysteroid dehydrogenase. 11β-HSD are enzymes involved in the regulation of the level of active glucocorticoids in different tissues. There are two isoforms, 11β-HSD1 and 11β-HSD2, with opposing functions. In Human, 11β-HSD2 catalyzes the reversible conversion of active cortisol to the inactive 11-keto derivative cortisone, whereas 11β-HSD1 can function both as a reductase and as a dehydrogenase to catalyze both the activation and deactivation of the glucocorticoid. GA is an efficient non-selective inhibitor of both enzymes ([@bb0415]). This activity supports the use of GLR in the protection of bone against glucocorticoid-induced osteoporosis ([@bb0720]).

GLR is a multi-target compound and novel potential targets are regularly disclosed. For example, in silico molecular docking has predicted that GLR binds to the Nrf2 (Nuclear factor-E2 related factor 2) peptide binding site on Keap-1 (Kelch like ECH-associated protein 1) and thus can possibly function as a Nrf2 stimulator ([@bb0390]). GLR exerts Nrf2-dependent activities ([@bb0320]; [@bb0645]) but thus far a direct, physical interaction with Keap-1 has not been evidenced. Another recent study revealed that GLR (as well as its analogues GA and carbenoxolone (18β-glycyrrhetinic acid 3β-O-hemisuccinate) are selective and competitive inhibitors of kynurenine aminotransferase 2 (KAT2), the enzyme which catalyzes the conversion of kynurenine to kynurenic acid ([@bb1105]). This inhibitory effect may contribute to the anti-Parkinson activity of GLR ([@bb0970]). GLR can also bind very weakly to nucleic acids, both DNA and RNA ([@bb0655]; [@bb0660]).

11. GLR and drug combinations: focus on chloroquine and tenofovir {#s0055}
=================================================================

GLR can be easily combined with many types of drugs, either to promote solubilization and bioavailability of the co-transported product as discussed above, or to complement its mechanism of action leading to synergistic effects in some cases ([@bb0540]; [@bb1140]). We will not review here all combinations previously reported, but only focus on two combinations useful in the context of coronavirus infections, with the antiviral drugs chloroquine and tenofovir.

As mentioned above, chloroquine downregulates HMGB1 expression and reduces HMGB1 serum level in a model of acute liver injury ([@bb0190]). Given the therapeutic potential of chloroquine against SARS-CoV-2 ([@bb0165]; [@bb0235]), it could make sense to consider both GLR and chloroquine for the treatment of the current pandemia. Human viruses exploit the autophagy pathway to help viral propagation and escape immune response ([@bb0005]). In particular, coronavirus infection has been demonstrated to induce autophagy ([@bb0160]; [@bb0560]), notably through the membrane-associated papain-like protease PLP2 (PLP2-TM) acting as an autophagy-inducing protein, via a direct interaction with the key autophagy regulators LC3 and Beclin1 ([@bb0140]). For example, the porcine viruses PEDV and PHEV both induce autophagy to benefit their replication ([@bb0205]; [@bb0295]; [@bb0290]). As another example, the mycotoxin ochratoxin A induces autophagy to promote porcine circovirus type 2 (PCV2) replication, whereas inhibitors of autophagy such as 3-methylademine and chloroquine significantly attenuate PCV2 replication ([@bb0695]). Consequently, interfering with the autophagy process could perturb coronavirus infection. Autophagy inhibition can be induced by chloroquine (or hydroxychloroquine), leading to inhibition of virus replication. For example, chloroquine-induced inhibition of autophagy suppresses the replication of the hepatitis C virus ([@bb0625]). GLR has been shown also to modulate autophagy in different cell systems, although both inhibition ([@bb0370]) and activation ([@bb0700]; [@bb0930]; [@bb1080]) of autophagy have been reported. However, it has been shown that HMGB1 translocation and release induce autophagy in lung macrophages and this process can be attenuated via the blockade of HMGB1 with GLR ([@bb0430]). Moreover, the use of an autophagy inhibitor enhances the anticancer activity of GA ([@bb0115]; [@bb0805]). Thus, we believe that the combination of GLR and (hydroxy)chloroquine could be useful to inhibit coronavirus replication. Chloroquine is hydrophilic compound, relatively well absorbed orally and with good bioavailability. It exhibits linear absorption and clearance ([@bb0710]; [@bb1165]). However, the entrapment of chloroquine into multilamellar vesicles has been shown to enhance drug delivery ([@bb0240]).

Tenofovir (Viread®, TDF, [Fig. 9](#f0045){ref-type="fig"} ) is a nucleotide analog reverse-transcriptase inhibitor widely used as the first-line therapy to inhibit hepatitis B virus replication. It is also a recommended first-line drug for HIV treatment. The combination of tenofovir and GLR has been investigated in a pilot clinical study with a cohort of patients with severe acute exacerbation of chronic hepatitis B and showed that the early introduction of GLR can be safe and beneficial for those patients difficult to manage ([@bb0350]). The molecular basis of this benefit is not known but a hypothesis can be advanced because it was shown GA increases distribution in the cytoplasm and nucleus of liver cells of the related antiviral drug entecavir ([@bb0130]). On the other hand, a recent molecular modeling study has suggested that tenofovir binds tightly to the RNA-dependent RNA polymerase of the SARS-CoV-2 virus and thus could be a useful antiviral agent ([@bb0225]). A clinical trial including tenofovir and other antiviral agents is on-going in China ([@bb1135]; [@bb1185]). The convergence of these pieces of information led us to consider also the combination of GLR and tenofovir as a potential anti-coronavirus approach.Fig. 9Chemical structures of two saponins (platycodin D and saikosaponin A), and two drugs that could be combined with GLR (chloroquine and tenofovir), mentioned in this study.Fig. 9

12. Other saponins with activities against coronavirus {#s0060}
======================================================

The membrane-perturbating effects of GLR have been also observed with other structurally related saponins such as platycodin D ([Fig. 9](#f0045){ref-type="fig"}) and β-escin ([@bb0040]). These two natural products interact with cholesterol thereby modulating the organization of lipid rafts in membranes. This activity likely contributes to their biological activity, in particular to the antiviral effects reported with both products ([@bb0400]) and their adjuvant properties to increase immunogenicity of proteins and vaccines ([@bb1050], [@bb1055]). Escin has been recently proposed as add-on therapy in acute lung injury related to COVID-19 infection ([@bb0265]). Platycodin D has been characterized as a potent inhibitor of PPRSV infection in vitro, directly inhibiting the virus replication and reducing the production of different virus-induced cytokines ([@bb1145]). A recent modeling study indicated that this saponin derivative presents a high binding affinity to papain-like protease of SARS-CoV-2 ([@bb1040]). We must also mention the saikosaponins, structurally close to GLR, which have been characterized for their antiviral effects against coronavirus 229E. Saikosaponin B2 inhibited viral attachment and penetration, and virus infection ([@bb0145]). This plant glycoside (a component of the traditional Chinese herbal medicine xiao-chai-hu-tang) is also active against the HBV and HCV viruses ([@bb0450]). Saikosaponin A ([Fig. 9](#f0045){ref-type="fig"}) was found to be active against different influenza A virus strains (including a pathogenic H5N1 strain) ([@bb0110]) and saikosaponins A and D showed interesting activities against porcine circovirus 2 (PCV2) ([@bb1085]), as well as PPRSV infections, enhancing the immune responses and decreasing the incidence and severity of PRRSV-induced immunopathological damages in vivo ([@bb0330]). We consider this information as indirect element to support the potential use of a saponin like GLR for the treatment of coronavirus infections. GLR is a relatively safe product, well tolerated, inducing limited undesirable effects and used for a long time in medicine, whereas saponins like platycodin D and saikosaponin A are only laboratory tools, not drugs. Moreover, the HMGB-1 binding activity is specific to GLR, therefore making this natural product a unique drug to be further considered.

13. Conclusion {#s0065}
==============

GLR is a well-established oriental phytomedicine used for a long time to treat hepatic disorders. The production of the drug is securitized, and drug products of good quality can be found easily. Our scientific analysis highlighted the following main characteristics ([Fig. 10](#f0050){ref-type="fig"} ):-GLR is considered a safe natural product, with a long-established use in Human as a hepato-protecting agent. Adverse effects are relatively rare and manageable ([@bb0665]).-GLR is used in Human for the treatment of chronic hepatitis (and other liver diseases) and has shown marked activity against some coronaviruses such as the porcine virus PEDV. It is also used to treat cutaneous inflammation.-The anti-inflammatory activity of GLR could be useful to alleviate the respiratory distress syndrome associated to the viral infection.-There is no obstacle to the combination of GLR with a variety of drugs and its combination with antiviral drugs such as chloroquine or tenofovir could be beneficial. GLR, which can be administered iv and orally, can serve as a codrug to increase the bioavailability of poorly soluble products. It makes sense also to combine GLR with other antiviral agents having different mechanisms to reinforce the antiviral response (combination of cytoplasmic and membrane effects).-GLR induces cholesterol-dependent disorganization of lipid rafts which are important for the entry of coronavirus into cells. These membrane effects, also observed with other amphiphilic saponins, likely play an important role in the antiviral activity. GLR is considered a non-hemolytic saponin.-GLR is an efficient binder of HMGB1. The glycoside moiety of GLR plays a major role in the interaction with the HMG box protein. Considering the multiple functions of HMGB1 in viral infections and replication, the trapping of HMGB1 by GLR could contribute significantly to a diminution of the virus-induced excessive inflammatory response and the viral replication. Fig. 10Summary of the main characteristics and properties of GLR, supporting its potential activity against the SARS-CoV-2 coronavirus. The drug is safe, used for a long time to treat viral hepatitis (iv and oral formulations available). GLR binds to cholesterol, thereby affecting the organization of lipid rafts that are essential for the entry of the virus into cells. GLR forms stable complexes with HMGB1 protein, thereby blocking the propagation of the danger signals. GLR displays antiviral activities against multiple viruses, including hepatitis virus A-B-C and some coronavirus.Fig. 10

For all these reasons, we believe that GLR should be rapidly tested as an anti-SARS-CoV-2 agent, alone and in combination with other drugs (notably CQ/HCQ and tenofovir) to combat the current COVID-19 pandemic.

While this manuscript was reviewed, three groups also proposed the use of GLR, alone or in combination with other drugs, to treat coronavirus infections ([@bb0125]; [@bb0550]; [@bb1170]). Notably, one study underlined the capacity of GLR to bind to the angiotensin converting enzyme 2 (ACE2) which represents a SARS-CoV-2 receptor. Therefore, the targeting of ACE2 could be very useful to inhibit the virus from diffusing out of infected cells and to enter new cells ([@bb0550]). Even more recently, a study reported interesting clinical data for a patient with severe COVID-19 who recovered upon treatment with diammonium glycyrrhizinate ([@bb0200]). These data are encouraging and support our proposal to clinically evaluate GLR as a drug to treat SARS-CoV-2 infections, considering notably that the drug and derivatives have shown activity against other SARS-coronavirus ([@bb0325]). The risk of hypertension induced by GLR, due to pseudo-hyperaldosteronism, should not be neglected ([@bb0495]; [@bb0455]) but in the current situation, without an efficient treatment, it is worth evaluating the antiviral benefit of this drug of natural origin.
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[^1]: SASA calculated with a probe of 1.4 Å radius. Drug properties were calculated with the BOSS 4.9 software ([@bb0380]) according to published procedures ([@bb0425]; [@bb0945]).

[^2]: In silico molecular docking procedure. The 3D structure of HMG box \[[@bb1030]\] was retrieved from the Protein Data Bank ([www.rcsb.org](http://www.rcsb.org){#ir0010}) under the PDB code [1HME](pdb:1HME){#ir0015}. Docking experiments were performed with the GOLD software (Cambridge Crystallographic Data Centre, Cambridge, UK). The drug-HMG structures have been optimized using a classical Monte Carlo conformational searching procedure as described in the BOSS software ([@bb0380]). Ligands are defined as flexible during the docking procedure. For each ligand, up to 30 poses that are energetically reasonable were kept while searching for the correct binding mode of the ligand. The decision to keep a trial pose is based on ranked poses, using the PLP fitness scoring function (which is the default in GOLD version 5.3 used here). In addition, an empirical potential energy of interaction ΔE for the ranked complexes is evaluated using the simple expression ΔE(interaction) = E(complex) - (E(protein) + E(ligand)). For that purpose, the Spectroscopic Empirical Potential Energy function SPASIBA and the corresponding parameters were used ([@bb0425]; [@bb0945]). Molecular graphics and analysis were performed using the Discovery Studio 2020 Client software, Dassault Systemes Biovia Corp.
